Sunstone
← All Articles
chagamushroomsadaptogensimmune healthantioxidantsnatural healthInonotus obliquusfunctional mushrooms

Chaga Mushroom: Evidence-Based Benefits and Practical Use

22 February 2026 · 21 min read

Among the functional mushrooms attracting serious scientific attention, Chaga (Inonotus obliquus) occupies a distinctive niche. Unlike the fruiting-body mushrooms most people picture, Chaga is technically a sclerotium — a hardened, charcoal-black mass that forms where a parasitic fungus colonises birch trees across boreal forests in Siberia, Russia, Canada, Scandinavia, and northern Korea. Indigenous Siberian peoples brewed it as a tea for centuries, and Russian folk medicine formalised its use for gastrointestinal complaints and general vitality long before modern pharmacognosy confirmed what the bioactive chemistry was actually doing.

What makes Chaga pharmacologically interesting is not one dominant compound but an unusually dense convergence of compound classes: triterpenoids derived from the birch host, melanin pigments with exceptional free-radical-scavenging capacity, beta-glucan polysaccharides with immune-signalling activity, and enzymes including superoxide dismutase (SOD) at concentrations rarely matched in the food world. The result is a compound profile that intersects antioxidant, immune-modulatory, anti-inflammatory, and adaptogenic territory simultaneously.

This article works through that compound profile systematically, evaluates where the human evidence is meaningful and where it remains preclinical, and provides a practical guide to extraction, quality markers, dosing, and interactions — including the Australian regulatory context.

What Is Chaga? Taxonomy, Habitat, and Traditional Use

Inonotus obliquus belongs to the Hymenochaetaceae family of basidiomycete fungi — the same broad phylum (Basidiomycota) that includes reishi (Ganoderma lucidum) and turkey tail (Trametes versicolor), though Chaga's growth form sets it apart from both. It is a pathogenic parasite: its mycelium penetrates birch bark and colonises the heartwood, drawing nutrients from the living tree over 10–20 years before the sclerotium — the black, externally charred mass — becomes large enough to harvest. Strictly speaking, this sclerotium is a sterile conk rather than a true fruiting body; the actual spore-producing structure of I. obliquus is a thin, crust-like layer that forms beneath the bark only as the host tree is dying, and is rarely seen in the field. Harvesting the conk kills the fungus. The exterior melanin crust forms as a direct response to UV exposure and oxidative stress; the interior is orange-brown and contains the bulk of the bioactive compounds.

Traditional Siberian use centred on birch-brewed Chaga tea as a general wellness tonic and remedy for gastrointestinal discomfort. Russian healers in the 16th century documented its use for intestinal complaints and stomach ailments, and the Soviet pharmacopoeia formally recognised Inonotus obliquus extract (branded as Befungin) in 1955 following early clinical observations. That historical lineage informs why much of the foundational Chaga research originates from Russian and Eastern European laboratories.

Key Bioactive Compounds

Chaga's pharmacological breadth stems from six primary compound classes, each with distinct mechanisms.

Betulinic Acid and Betulin

These pentacyclic triterpenes are the most clinically discussed compounds in Chaga, and they arrive indirectly: Chaga enzymatically converts betulin and betulinic acid from the birch bark it colonises, concentrating these compounds at levels unavailable in birch bark alone. Betulinic acid has attracted substantial preclinical interest for its pro-apoptotic activity — it appears to trigger mitochondria-mediated apoptosis selectively in certain tumour cell lines by activating caspase cascades and altering Bcl-2/Bax ratios. This is promising mechanistic data, but the evidence is overwhelmingly in vitro and in animal models. No human clinical trials have demonstrated anti-tumour efficacy in Chaga-consuming populations, and betulinic acid should not be interpreted as a cancer treatment.

Polysaccharides and Beta-Glucans

Beta-1,3/1,6-D-glucans are the primary immunologically active fraction. These water-soluble carbohydrate polymers bind to pattern recognition receptors — particularly Toll-like receptor 2 (TLR2) and Dectin-1 — on the surface of innate immune cells including macrophages, natural killer (NK) cells, and dendritic cells. Dectin-1 engagement activates the Syk kinase pathway and downstream NF-κB signalling, enhancing phagocytic capacity and NK cell cytotoxicity. Because this is immunomodulatory rather than bluntly stimulatory, beta-glucans appear to calibrate immune readiness without driving excessive inflammatory output — a distinction that matters clinically.

Melanin Complex

Chaga's black exterior is composed of one of the most concentrated natural melanin complexes found in any biological material. This high-molecular-weight pigment has potent free-radical-scavenging activity. Research measuring ORAC (oxygen radical absorbance capacity) values has consistently placed Chaga extract among the highest of any natural food or supplement tested, with some preparations exceeding 50,000 ORAC units per gram. The melanin complex also shows UV-protective and DNA-stabilising effects in cell culture models, though human bioavailability of intact melanin complexes requires further characterisation.

Superoxide Dismutase (SOD)

Chaga contains biologically active SOD — an enzyme that catalyses the dismutation of superoxide radicals (O₂·⁻) into less reactive hydrogen peroxide and oxygen. SOD activity measured in Chaga preparations consistently ranks among the highest recorded for any fungal or botanical material. Superoxide is one of the primary reactive oxygen species generated during normal cellular metabolism and is implicated in accelerated cellular ageing and inflammatory tissue damage. While oral SOD faces bioavailability questions (the enzyme may be degraded in the GI tract), some research suggests low-molecular-weight fragments retain partial activity, and the polysaccharide matrix may offer some protection.

Triterpenoids

Beyond betulinic acid and betulin, Chaga contains a broader array of lanostane-type triterpenoids including inotodiol, lanosterol, and ergosterol derivatives. These lipid-soluble compounds require ethanol extraction and are not present in meaningful quantities in plain hot water preparations. Triterpenoids contribute to the adaptogenic character of Chaga — they appear to modulate HPA axis activity in animal stress models — and several show COX-2 inhibitory activity relevant to anti-inflammatory mechanisms.

Sterols and Phenolic Compounds

Chaga also contains phytosterols (including ergosterol, a precursor to vitamin D₂), various flavonoids, and phenolic acids including protocatechuic acid. These contribute to the antioxidant activity profile and likely to the mild hepatoprotective effects observed in some animal studies.

Antioxidant Capacity: Among the Highest Recorded

The combination of the melanin complex, SOD, beta-glucans, phenolic acids, and triterpenoids gives Chaga an antioxidant profile that is genuinely exceptional by measured standards. ORAC testing — while imperfect as a predictor of in vivo antioxidant effect — has placed quality Chaga extracts at 25,000–50,000+ ORAC units per gram, compared to blueberries at approximately 4,600 ORAC units per 100g.

More mechanistically relevant is the direct SOD activity. Oxidative stress — the imbalance between reactive oxygen species production and endogenous antioxidant capacity — is implicated in inflammation, accelerated cellular ageing, and metabolic dysfunction. Chaga's multi-pathway antioxidant action (enzymatic via SOD, pigment-based via melanin, and small-molecule via phenolics) makes it distinct from single-pathway antioxidant supplements like vitamin C or vitamin E.

For context on antioxidant mechanisms in cellular longevity, the article on NAD and cellular longevity explores how mitochondrial redox balance influences ageing — Chaga's SOD activity operates in a complementary lane by reducing the superoxide load that NAD-dependent pathways must manage.

Immune Modulation: The Beta-Glucan Pathway

The most evidence-supported mechanism for Chaga's immune effects runs through beta-glucan signalling. When beta-glucans bind TLR2 and Dectin-1, the downstream effects include:

  • Increased macrophage activation and phagocytic capacity
  • Enhanced NK cell cytotoxicity — relevant to immune surveillance of aberrant cells
  • Upregulation of cytokine signalling including TNF-α and interleukin-6 (IL-6) in acute contexts, with modulation toward balanced output over sustained use
  • Dendritic cell maturation, supporting adaptive immune priming

Several mouse and in vitro studies have demonstrated meaningful NK cell activation following Chaga polysaccharide administration. A 2015 study in Food and Chemical Toxicology showed that Chaga polysaccharides enhanced NK cytotoxic activity and spleen lymphocyte proliferation in animal models. Human RCT data on immune activation is limited, though the beta-glucan mechanism is well-established from research across multiple functional mushrooms — including Turkey Tail, which carries the strongest human clinical evidence base in this area (see our article on Turkey Tail mushroom and immune research).

Anti-Inflammatory Pathways

Chaga's anti-inflammatory activity operates through several complementary mechanisms, best characterised in cell culture and animal models:

NF-κB inhibition: Several Chaga extracts and isolated compounds (particularly inotodiol and betulinic acid) have demonstrated dose-dependent suppression of NF-κB pathway activation in macrophage cell lines. NF-κB is a master transcription factor governing the expression of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. Its inhibition is a shared mechanism with other anti-inflammatory natural compounds including curcumin.

COX-2 downregulation: Triterpenoid fractions from Chaga show selective COX-2 inhibitory activity in vitro, comparable in mechanism (though not necessarily in potency) to selective NSAID drugs. COX-2 drives prostaglandin synthesis and is upregulated in chronic inflammatory states.

IL-6 modulation: IL-6 is a pleiotropic cytokine — pro-inflammatory in acute contexts but playing regulatory roles in immune activation. Chaga extracts have shown bidirectional IL-6 modulation in animal models depending on the inflammatory context, consistent with an adaptogenic rather than bluntly suppressive mode of action.

Importantly, the anti-inflammatory evidence is predominantly preclinical. No large-scale human RCTs have confirmed clinically meaningful anti-inflammatory effects of Chaga supplementation in humans. Individuals with inflammatory conditions should not substitute Chaga for evidence-based treatments.

Adaptogenic Properties and HPA Axis Modulation

Chaga is increasingly classified as an adaptogen — a compound that helps the organism resist and recover from physical and biochemical stressors without a specific pharmacological endpoint. The mechanistic basis appears to involve HPA (hypothalamic-pituitary-adrenal) axis modulation: animal studies have shown that Chaga polysaccharide administration reduces corticosterone elevation following acute stress exposure, and that chronic supplementation attenuates stress-induced immune suppression.

This places Chaga in the functional category alongside Ashwagandha (Withania somnifera), Reishi, and Rhodiola rosea. Where Ashwagandha's adaptogenic mechanisms are primarily driven by withanolide modulation of cortisol and GABAergic pathways, Chaga's stress-modulating effects appear more dependent on its polysaccharide and triterpenoid fractions acting upstream at the immune-neuroendocrine interface. The practical implication is that they may complement each other — operating through different molecular entry points to reach similar functional outcomes around stress resilience and immune competence.

Human clinical data on Chaga's adaptogenic effects is essentially absent. This remains a biologically plausible but unproven area of activity in humans.

Blood Glucose Effects

Chaga has shown meaningful anti-diabetic activity in multiple animal models, through two primary mechanisms:

Alpha-glucosidase inhibition: Chaga extracts inhibit alpha-glucosidase, an intestinal enzyme responsible for breaking dietary carbohydrates into absorbable glucose. Inhibiting this enzyme slows post-meal glucose absorption — the same mechanism as the pharmaceutical drug acarbose. Several in vitro and murine studies have confirmed this activity for Chaga polysaccharide and phenolic fractions.

Insulin sensitisation: In streptozotocin-induced diabetic mouse models, Chaga polysaccharide administration has reduced fasting blood glucose, improved glucose tolerance curves, and partially restored pancreatic beta-cell function. The mechanism appears to involve AMPK activation and downstream improvement in GLUT-4 translocation — the same pathway targeted by metformin.

These findings are pharmacologically interesting but require significant translation caution. Animal studies of blood glucose effects use controlled experimental conditions that do not reflect dietary complexity in humans. No adequately powered human RCTs have confirmed clinically meaningful blood glucose lowering from Chaga supplementation. However, the alpha-glucosidase inhibition mechanism raises a genuine interaction concern: people taking anti-diabetic medications (metformin, GLP-1 agonists, SGLT-2 inhibitors, or insulin) should discuss Chaga supplementation with their healthcare provider before starting, as additive effects on blood glucose lowering are plausible.

Antiviral Research: In Vitro Findings and Their Limits

In vitro studies have investigated Chaga extracts against several viruses. A 2015 study published in Phytomedicine found that Chaga extract demonstrated inhibitory activity against influenza virus replication in Madin-Darby canine kidney (MDCK) cell cultures. Separate in vitro work has shown activity against herpes simplex virus (HSV-1 and HSV-2), with the polysaccharide fraction appearing to interfere with viral entry into host cells.

It is essential to note the limitations of in vitro antiviral data explicitly: cell culture antiviral activity does not predict meaningful antiviral effect in living organisms. Factors including bioavailability, protein binding, immune clearance, and tissue distribution all intervene between a petri dish result and a clinical outcome. Chaga should not be treated as an antiviral agent for any human infection. The in vitro findings are hypothesis-generating — they identify mechanisms worth investigating in animal and eventually human models.

Key Studies Behind the Evidence

A handful of specific studies are cited repeatedly across the Chaga literature and are worth naming directly, alongside a clear read of what each one does and does not establish:

  • Pisha et al. (1995), published in Nature Medicine, reported that betulinic acid induced apoptosis selectively in human melanoma cell lines while sparing normal melanocytes — a landmark demonstration of selective cancer-cell toxicity at the compound level, achieved through mitochondrial apoptotic pathway activation. This remains laboratory research, not clinical evidence that Chaga treats cancer.
  • Youn et al. (2009) examined Chaga extract in a murine lipopolysaccharide (LPS) inflammation model, finding significant reductions in pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and suppressed nitric oxide production in macrophage cell culture, attributed largely to iNOS suppression and NF-κB modulation.
  • Kim et al. (2011) investigated Chaga polysaccharide's immunostimulatory effects on splenocyte populations, finding significant stimulation of lymphocyte proliferation and NK cell activity in murine cell preparations.
  • Glamočlija et al. (2015) conducted broad antiviral screening of Inonotus obliquus extracts, identifying inhibitory activity against several viral targets in cell culture assays across both aqueous and ethanol fractions, with potency varying by extract type and viral target.

Each of these is preclinical (cell culture or animal) evidence. They establish mechanistic plausibility and are the reason Chaga continues to attract serious research interest — but none of them constitute clinical proof of efficacy in humans, and none should be read as license to substitute Chaga for evidence-based medical treatment.

Chaga vs Reishi vs Turkey Tail: Comparison Table

| Feature | Chaga | Reishi | Turkey Tail | |---|---|---|---| | Botanical form | Sclerotium (parasitic on birch) | Fruiting body (shelf fungus) | Fruiting body (shelf fungus) | | Primary bioactives | Betulinic acid, melanin, beta-glucans, SOD | Ganoderic acids, beta-glucans, adenosine | PSK/PSP polysaccharides, beta-glucans | | Standout mechanism | Antioxidant (SOD + melanin), immune modulation | Adaptogenic (HPA axis), immune modulation, sleep | Immune modulation, gut microbiome support | | Antioxidant capacity | Exceptional (highest ORAC among mushrooms) | Moderate | Low–moderate | | Immune evidence | Preclinical + limited animal | Preclinical + some human data | Strongest human clinical data (PSK trials) | | Adaptogenic evidence | Animal models | Animal models + some human | Limited | | Best extraction | Dual extraction (hot water + ethanol) | Dual extraction | Hot water (polysaccharides primary) | | Evidence level | Preclinical dominant | Mixed preclinical/clinical | Strongest clinical base (oncology support) |

For a deeper look at Reishi's ganoderic acid research and immune mechanisms, see our Reishi mushroom benefits guide. All three mushrooms are considered part of the core functional mushroom trio for immune-focused supplementation, each contributing through overlapping but distinct mechanisms.

Forms, Extraction Methods, and What to Look For

Extraction method is the single most important quality variable in Chaga supplementation. Different compound classes require different solvents, and a product that omits a step will be missing that fraction entirely.

Hot Water Extract

Hot water extraction (decoction at 80–100°C) releases and concentrates the water-soluble compounds: beta-glucan polysaccharides, melanin pigments, and polyphenols. A quality hot water extract should list beta-glucan content — look for a minimum of 20–30% beta-glucans by weight. This is the traditional preparation method and the appropriate choice if immune modulation and antioxidant activity are the primary goals.

Ethanol Extract

Alcohol extraction (typically 40–70% ethanol) solubilises the lipid-soluble triterpenoids: betulinic acid, betulin, inotodiol, and lanostane derivatives. These are absent in hot water-only extracts. Ethanol extraction alone misses the polysaccharide fraction.

Dual Extraction

Dual extraction combines sequential hot water and ethanol extraction to deliver both fractions in a single product. This is the recommended preparation for comprehensive benefits. Quality dual extracts will often specify both beta-glucan content (polysaccharide fraction) and list triterpenoids or betulinic acid on the certificate of analysis. This preparation is available as capsules, powder, and tincture.

Forms Guide

| Form | Extraction | Best For | Notes | |---|---|---|---| | Powder (dual extract) | Dual | General use, flexibility | Mix into coffee, tea, or smoothies; check beta-glucan % | | Tincture | Usually dual | Rapid absorption, travel | Typically 1:4 or 1:5 ratio; confirm dual extraction on label | | Capsule (dual extract) | Dual | Convenience, precise dosing | Easiest for consistent daily use | | Raw powder (non-extracted) | None | Not recommended | Poor bioavailability; compounds not released from chitin matrix | | Hot water only | Water | Budget option for polysaccharides | Lacks triterpenoid fraction |

Birch-Sourced vs Mycelium on Grain

This is the most critical sourcing distinction in Chaga:

  • Wild-harvested or birch-cultivated sclerotium is the authentic source. Betulinic acid and betulin accumulate specifically because Chaga is parasitising birch — these compounds come from the birch host tree and concentrate in the sclerotium over years. Wild birch-sourced Chaga has dramatically higher betulinic acid content.
  • Mycelium grown on grain substrate (oats, rice, brown rice) is a common cost-cutting approach in the supplement industry. Mycelium-on-grain products contain significant quantities of the grain substrate, diluting the active compound content. They cannot accumulate betulinic acid from a birch host. Third-party testing showing the starch content — which should be <5% in a quality extract; grain-based products often exceed 30% — is a key quality indicator.

Always look for: wild-harvested or birch-cultivated Chaga, dual extraction specified, beta-glucan content stated (minimum 20–30%), third-party COA (certificate of analysis), and no grain filler.

Dosing

Research studies and traditional use converge on a similar practical dosing range for Chaga extract:

  • Standard dose: 1–2g per day of a dual-extracted Chaga extract, standardised to beta-glucan content
  • Traditional tea equivalent: 3–5g of raw Chaga chunk simmered for 30–60 minutes, producing a lower but bioavailable dose of water-soluble compounds
  • Cycle vs continuous use: Some practitioners recommend cycling (e.g., 5 days on, 2 days off, or 8 weeks on, 2 weeks off) based on the adaptogen tradition, though no human data confirms this is necessary
  • Timing: No robust evidence guides timing; consistency matters more than time of day

Higher doses have been used in animal studies without reported toxicity signals, but extrapolating animal dosing to human safety is not straightforward. Starting at the lower end of the range (1g/day) and assessing tolerance over 2–4 weeks is a sensible approach.

Interactions and Precautions

Chaga has a specific interaction profile that warrants attention:

Anticoagulants and antiplatelet agents: Chaga contains oxalate compounds and has demonstrated platelet aggregation inhibitory activity in vitro. Combined with anticoagulant medications (warfarin, apixaban, rivaroxaban, dabigatran) or antiplatelet agents (aspirin, clopidogrel), there is a plausible risk of additive bleeding effect. People on anticoagulation therapy should not take Chaga without explicit medical clearance.

Diabetes medications: As noted above, the alpha-glucosidase inhibitory activity creates additive hypoglycaemic risk with anti-diabetic medications. Monitor blood glucose more closely if combining.

Immunosuppressant medications: The immune-activating properties of Chaga beta-glucans may theoretically counteract immunosuppressive drugs used in transplant patients or autoimmune disease management. This is mechanistically plausible but not well-documented in human case series.

Kidney oxalate load: Chaga is high in oxalates. People with a history of calcium oxalate kidney stones should use Chaga cautiously and maintain adequate hydration. Extended high-dose use in individuals with pre-existing kidney disease has been associated with oxalate nephropathy in rare case reports.

Australian Sourcing and TGA Context

In Australia, Chaga products are regulated under the Therapeutic Goods Administration (TGA) framework as listed medicines (AUST L) when making specific health claims, or sold as food supplements with general wellness language. The TGA does not approve Chaga extracts for treatment of any specific medical condition, and products making therapeutic claims must meet evidence requirements proportional to the claim strength.

When sourcing in Australia, look for:

  • Products listing their country of origin — Siberian or Canadian wild-harvested Chaga is preferred
  • Third-party testing documentation, ideally from Australian NATA-accredited labs or internationally recognised testing organisations
  • Clear dual extraction labelling and beta-glucan percentage on the label
  • Compliance with Therapeutic Goods (Permissible Ingredients) Determination standards

Australian consumers exploring the broader landscape of natural compounds can find additional context on immune-supporting peptide research and how natural compounds intersect with peptide-based approaches to immune and cellular health.

Frequently Asked Questions

Q: Can Chaga be taken every day long-term?

There is no established maximum duration from human clinical trials. Traditional use in Siberian populations involved daily consumption, often as tea, over extended periods. The primary caution for long-term use is the oxalate content — people with kidney stone history or reduced kidney function should monitor more carefully and ensure adequate hydration. For most healthy adults, daily use at standard extract doses (1–2g) appears well-tolerated based on available safety data, though this has not been formally studied in long-duration human trials.

Q: Does Chaga actually support immune function?

The beta-glucan fraction modulates immune signalling — activating pattern recognition receptors and enhancing NK cell function — in ways that may improve immune surveillance and responsiveness. This is meaningfully different from indiscriminately amplifying inflammatory output. The evidence is primarily from in vitro and animal studies; human RCT evidence for clinically measurable immune benefit from Chaga specifically is limited. For the strongest evidence base on beta-glucan immune modulation across medicinal mushrooms, Turkey Tail's PSK research in oncology adjuvant settings remains the benchmark.

Q: Is Chaga safe if I have an autoimmune condition?

The immune-activating properties of Chaga raise theoretical concern in autoimmune disease — stimulating immune activity could exacerbate conditions where the immune system is already overactive. This concern is mechanistically plausible but not well-documented in human clinical reports. People with autoimmune conditions (rheumatoid arthritis, lupus, multiple sclerosis, inflammatory bowel disease) should discuss Chaga supplementation with their rheumatologist or specialist before starting, particularly if taking immunosuppressant medications.

Q: What does Chaga taste like, and how do I take it?

Chaga brewed as a tea has a mild, earthy flavour with slight bitterness and a hint of vanilla — significantly more palatable than Reishi, which is distinctly bitter. Dual-extract powder can be stirred into black coffee (a popular traditional pairing that complements the flavour), hot chocolate, or smoothies. Capsules are flavourless and the most convenient for consistent dosing. Tinctures can be added to water or taken directly.

Q: How is Chaga different from Lion's Mane or Reishi?

Each functional mushroom has a distinct primary mechanism. Lion's Mane is focused on nerve growth factor (NGF) stimulation and cognitive function, with its hericenone and erinacine compounds working through a neurotrophin pathway largely absent in Chaga. Reishi's primary distinction is its ganoderic acid triterpenoid profile and well-characterised adaptogenic and sleep-quality effects. Chaga stands apart through its exceptional antioxidant depth (melanin complex + SOD), the birch-derived betulinic acid fraction, and its combination of immune modulation with anti-inflammatory triterpenoids. They are not interchangeable, but their mechanisms complement each other for those following a broader functional mushroom protocol.

Summary

Chaga mushroom (Inonotus obliquus) presents one of the most pharmacologically complex profiles of any functional mushroom, combining birch-derived betulinic acid with a potent melanin-based antioxidant system, high SOD enzymatic activity, beta-glucan immune signalling, anti-inflammatory triterpenoids, and emerging glucose metabolism data. Its ORAC values and SOD activity are among the highest recorded for any natural material.

The evidence base is honest about where it sits: most of the compelling mechanistic data comes from in vitro and animal studies. The anti-tumour findings from betulinic acid are preclinical. The antiviral data is in vitro only. The blood glucose findings require human RCT confirmation. The area with the strongest cross-species evidence is antioxidant capacity and beta-glucan-mediated immune modulation — the two areas where traditional use and mechanistic science align most clearly.

For practical use, dual extraction from wild birch-sourced sclerotium is the minimum quality standard. Starting at 1g/day of a standardised extract and escalating based on tolerance is a reasonable approach. People on anticoagulants, diabetes medications, or immunosuppressants should seek medical advice before starting.

This article is for informational and educational purposes only. It does not constitute medical advice and should not be used to diagnose, treat, or prevent any health condition. If you are taking anticoagulant medications, diabetes medications, immunosuppressants, or have a kidney condition or autoimmune disease, consult your healthcare provider before adding Chaga to your supplement regimen.